O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+10.04%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$8.27B
AUM Growth
+$8.27B
(-0.65%)
Cap. Flow
-$508M
Cap. Flow
% of AUM
-6.15%
Top 10 Holdings %
Top 10 Hldgs %
34.32%
Holding
163
New
21
Increased
24
Reduced
50
Closed
15
Top Buys
| 1 |
Humana
HUM
|
$108M |
| 2 |
Cigna
CI
|
$87.3M |
| 3 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
$76.1M |
| 4 |
Molina Healthcare
MOH
|
$72.7M |
| 5 |
Sarepta Therapeutics
SRPT
|
$64.9M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$125M |
| 2 |
Biogen
BIIB
|
$91M |
| 3 |
Merck
MRK
|
$80.6M |
| 4 |
Select Medical
SEM
|
$74.3M |
| 5 |
Boston Scientific
BSX
|
$65.9M |
Sector Composition
| 1 | Healthcare | 95.17% |
| 2 | Financials | 0.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $401M | 4.82% | 2,881,103 -243,500 | -8% | -$33.8M |
|
|
TCDA
2
DELISTED
Tricida, Inc. Common Stock
TCDA
| $333M | 4.01% | 10,889,280 | – | – |
|
|
3
Biogen
BIIB
$19.4B
| $322M | 3.87% | 910,300 -257,600 | -22% | -$91M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $308M | 3.72% | 1,600,500 -192,100 | -11% | -$37M |
|
|
5
Boston Scientific
BSX
$156B
| $303M | 3.65% | 7,863,995 -1,710,700 | -18% | -$65.9M |
|
6
Ascendis Pharma
ASND
$11.8B
| $294M | 3.55% | 4,155,891 -257,400 | -6% | -$18.2M |
|
|
7
Merck
MRK
$210B
| $251M | 3.03% | 3,544,400 -1,135,600 | -24% | -$80.6M |
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $220M | 2.66% | 2,463,850 -106,800 | -4% | -$9.56M |
|
|
AGN
9
DELISTED
Allergan plc
AGN
| $219M | 2.64% | 1,150,405 -135,800 | -11% | -$25.9M |
|
|
WMGI
10
DELISTED
Wright Medical Group Inc
WMGI
| $187M | 2.25% | 6,439,568 +116,900 | +2% | +$3.39M |
|
11
Viatris
VTRS
$12.3B
| $175M | 2.11% | 4,779,600 +1,076,800 | +29% | +$39.4M |
|
12
Edwards Lifesciences
EW
$47.8B
| $172M | 2.08% | 990,600 +119,700 | +14% | +$20.8M |
|
13
Thermo Fisher Scientific
TMO
$186B
| $163M | 1.96% | 668,000 +84,500 | +14% | +$20.6M |
|
14
Regeneron Pharmaceuticals
REGN
$61.5B
| $159M | 1.92% | 394,400 +21,900 | +6% | +$8.85M |
|
15
Jazz Pharmaceuticals
JAZZ
$7.75B
| $149M | 1.79% | 884,000 -156,100 | -15% | -$26.2M |
|
|
16
Sarepta Therapeutics
SRPT
$1.78B
| $138M | 1.66% | 854,400 +401,800 | +89% | +$64.9M |
|
|
17
Humana
HUM
$36.5B
| $133M | 1.6% | 393,000 +320,400 | +441% | +$108M |
|
|
18
Cigna
CI
$80.3B
| $132M | 1.59% | 633,900 +419,100 | +195% | +$87.3M |
|
19
Elevance Health
ELV
$71.8B
| $130M | 1.56% | 474,000 -57,800 | -11% | -$15.8M |
|
20
Bristol-Myers Squibb
BMY
$96B
| $126M | 1.51% | 2,025,800 -354,500 | -15% | -$22M |
|
21
Puma Biotechnology
PBYI
$254M
| $124M | 1.49% | 2,705,181 -27,700 | -1% | -$1.27M |
|
|
CMTA
22
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $116M | 1.4% | 10,425,225 | – | – |
|
23
DaVita
DVA
$9.85B
| $104M | 1.25% | 1,445,700 -243,700 | -14% | -$17.5M |
|
24
Inspire Medical Systems
INSP
$2.77B
| $103M | 1.24% | 2,444,221 | – | – |
|
25
Illumina
ILMN
$15.8B
| $98.2M | 1.18% | 267,500 -17,000 | -6% | -$6.24M |
|